Sinovac Biotech Ltd banner

Sinovac Biotech Ltd
NASDAQ:SVA

Watchlist Manager
Sinovac Biotech Ltd Logo
Sinovac Biotech Ltd
NASDAQ:SVA
Watchlist
Price: 6.47 USD Market Closed
Market Cap: $644.7m

Wall St Price Targets

SVA Price Forecast
No price targets yet

We don't have analyst price targets for SVA yet.

SVA Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for SVA yet.

Sinovac Biotech Ltd Competitors:
Price Targets

Revenue
Forecast

17% / Year
Past Growth
-15% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
17% / Year
Past Growth
-15% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 11 years is -15%.

Gross Profit
Forecast

18% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
18% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Sinovac Biotech Ltd

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
20%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
20%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SVA's stock price target?
Not Available

SVA does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Sinovac Biotech Ltd?
Projected CAGR
-15%

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 11 years is -15%.

Back to Top